(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 January 2006 (05.01.2006)

PCT

(10) International Publication Number
WO 2006/001750 A1

(51) International Patent Classification[7]: C07D 471/04, A61K 31/435

(21) International Application Number: PCT/SE2005/000951

(22) International Filing Date: 20 June 2005 (20.06.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0401653-1 24 June 2004 (24.06.2004) SE

(71) Applicant *(for all designated States except US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BAUER, Udo** [DE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **BRAILSFORD, Wayne** [GB/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **CHHAJLANI, Vijay** [SE/US]; AstraZeneca Wilmington, P.O. Box 15437, 1800 Concord Pike, Wilmington, DE 19850-5437 (US). **EGNER, Bryan** [GB/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **FJELLSTRÖM, Ola** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **GUSTAFSSON, Linda** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **MATTSSON, Jan** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **NILSSON, Karolina** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **OLSSON, Thomas** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, S-151 85 Södertälje (SE).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IMIDAZOLE VARIANTS AS MODULATORS OF GABA RECEPTOR FOR THE TREATMENT OF GI DISORDERS



(I)

(57) Abstract: Box No. IV Text of the abstract (Continuation of item 5 of the first sheet) The present invention relates to novel compounds having a positive allosteric GÀBAB receptor (GDR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). A compound of the general formula I

WO 2006/001750 A1